The First and Only Medical Technology Designed for Both In-Clinic and At-Home Therapy of Resistant Depression
Disclaimer: Neurolief’s technology for the treatment of Major Depressive Disorder is considered investigational and therefore not yet granted marketing authorization.
Disclaimer: Neurolief’s technology for the treatment of Major Depressive Disorder is considered investigational and therefore not yet granted marketing authorization.
It’s time for a new era in mental healthcare. At Neurolief, we’re leading the way. Our mission is to bring relief to millions of people suffering from major depression.
A Global Epidemic of Depression. An Urgent Need for Solutions.
Major depressive disorder (MDD) is a global epidemic, impacting millions and inflicting severe emotional and physical suffering.
Despite its widespread prevalence, effective and accessible treatment options remain limited, especially for those with treatment-resistant depression (TRD) who fail to respond to conventional therapies. The situation is worsened by a significant shortage of psychiatrists, further increasing the barriers to access for those seeking care.
No effective home treatment exists for TRD, underscoring the urgent need for innovative solutions.
By addressing this unmet need we can transform mental healthcare, improve countless lives, and disrupt this stagnant market to significantly reduce the global burden of depression.
#0 Cause
of disability worldwide¹
0%
of US adults experience major depression²
>0
people die by suicide each year worldwide¹
>0%
of patients are resistant to traditional therapies¹
$ 0 Billion
the estimated annual economic burden of MDD in the US alone³
1 World health organization. Depression 2021 2 NIH – National Institute of Mental Health. Major Depression 2022 3 Greenberg PE et al. The Economic Burden of Adults with Major Depressive Disorder in the United States. Pharmacoeconomics. 2021 Jun;39 (6):653-665.
Breakthrough Therapy for Brain Networks Modulation
Neurolief’s groundbreaking therapy treats major depression by stimulating the release of neurotransmitters in the brainstem and modulating mood-related brain networks.
Our state-of-the-art medical technology utilizes three adaptive channels to non-invasively deliver precise electrical pulses through major neural pathways in the head, reaching the brainstem and higher brain regions implicated in depression. Designed for both in-clinic and at-home use, the system includes a wearable neuromodulation unit, a patient-friendly mobile app and a cloud-based data tracking and analytics. This advanced setup enables physicians to follow-up patients, analyze data and tailor treatments, thereby enhancing therapy outcomes.
Neurolief’s pioneering approach marks a major leap forward in the treatment of depression. By combining cutting-edge technology with personalized home-based care, we’re transforming the future of mental health and profoundly impacting the lives of those affected by depression.
Advanced Disease Management:
Physician-Enhanced Home Care
Our advanced platform expands physicians’ capabilities by bringing care directly into each patient’s home, significantly advancing depression management and extending the clinician’s ability to handle the growing number of these patients.
The Mood Study: Landmark Outcomes in Mental Health Therapy
The MOOD pivotal clinical study marks a historic landmark as the first ever Randomized Controlled Trial (RCT) to demonstrate success in a non-pharmacological home therapy for treatment-resistant depression.
For the first time, participants in the study achieved substantial improvement through a home-based therapy.
0%
of patients showed substantial clinical improvement*
*Improved at least 7 points in HDRS17
0%
of patients achieved full remission**
**After 16 weeks of treatment
0%
Unanticipated serious adverse events
Linda Carpenter, MD
Principal Investigator
Professor of Psychiatry
Warren Alpert Medical School
Brown University
“This is a great day for patients with depression!”
Mark George, MD
Professor of Psychiatry, Radiology and Neuroscience, and Director of the Center for Advanced Imaging Research and Brain Stimulation Laboratory at the Medical University of South Carolina (MUSC)
"This will have a tremendous impact on the approach for treating major depressive disorder."
Linda Carpenter, MD
Professor of Psychiatry at the Warren Alpert Medical School at Brown University and Chief of the Mood Disorders Program at Butler Hospital
Enhancing Lives with Neurolief’s Innovative Therapy for Treatment-Resistant Depression
Join us in transforming the future of mental healthcare and millions of lives worldwide.